Flavopiridol inversely affects p21WAF1/CIP1 and p53 and protects p21-sensitive cells from paclitaxel

被引:28
作者
Blagosklonny, MV
Darzynkiewicz, Z
Figg, WD
机构
[1] New York Med Coll, Branch Canc Res Inst, Hawthorne, NY 10532 USA
[2] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
flavopiridol; paclitaxel; p53; p21;
D O I
10.4161/cbt.1.4.21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resting cells are relatively resistant to microtubule-active drugs including paclitaxel (PTX). By causing p53-mediated arrest, pretreatment with low concentrations of doxorubicin (DOX) protected HCT116 cells from the cytotoxicity caused by PTX. Unlike DOX, flavopiridol (FL) did not protect HCT116 cells. Low concentrations of FL (50 nM) induced p21 but not p53. High concentrations of FL (500 nM) decreased levels of p21 and Mdm-2 but dramatically induced p53. Thus, FL reciprocally affects p21 and p53. In LNCaP, a prostate cancer cell line which is highly sensitive to p21-induced growth arrest (p21-sensitive), low concentrations of FL (50 nM) induced p21 (without induction of p53) and caused G1 and G2 arrest. This precluded mitotic arrest, Bcl-2 and Raf-1 phosphorylation, and diminished cell death caused by PTX. In contrast, FL did not protect PC3M, arrest-resitant and highly aggressive prostate cancer cells. Like LNCaP, HL60 and SKBr3 cells are known to be p21-sensitive. As predicted, low concentrations of FL antagonized PTX-mediated cytotoxicity in HL60 and SKBr3 cell lines. In summary, only low concentrations of FL can induce p21, and, in turn, only p21-sensitive cells are protected from PTX.
引用
收藏
页码:420 / 425
页数:6
相关论文
共 50 条
  • [31] Analysis of p53, p21Waf1/Cip1 and TGF-β3 immunohistochemical staining in Bowen's disease
    Kawakami, T
    Soma, Y
    Mizoguchi, M
    Saito, R
    DERMATOLOGY, 2001, 202 (01) : 9 - 15
  • [32] p21WAF1/CIP1 expression in colorectal carcinomas:: its correlation with p53 mutations and p53 and Ki67 immunohistochemistry.
    Chapusot, C
    Assem, M
    Martin, L
    Chalabreyssse, L
    Benhamiche, AM
    Lignier, MA
    Chauffert, B
    Teyssier, JR
    Faivre, J
    Piard, F
    PATHOLOGIE BIOLOGIE, 2001, 49 (02): : 115 - 123
  • [33] p21(Waf1/Cip1) and p53 protein expression in breast cancer
    Wakasugi, E
    Kobayashi, T
    Tamaki, Y
    Ito, Y
    Miyashiro, I
    Komoike, Y
    Takeda, T
    Shin, E
    Takatsuka, Y
    Kikkawa, N
    Monden, T
    Monden, M
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1997, 107 (06) : 684 - 691
  • [34] THE EXPRESSION AND SIGNIFICANCE OF P53 AND P21(WAF1/CIP1) IN THYROID CARCINOMA
    霍雄伟
    马清涌
    高燕凤
    孙学军
    刘浩
    盛薇
    Journal of Pharmaceutical Analysis, 2005, (01) : 86 - 89
  • [35] Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis
    Arai, N
    Mitomi, H
    Ohtani, Y
    Igarashi, M
    Kakita, A
    Okayasu, I
    MODERN PATHOLOGY, 1999, 12 (06) : 604 - 611
  • [36] Expression of p21WAF1/CIP1 and p53 proteins in gastric carcinoma:: its relationships with cell proliferation activity and prognosis
    Liu, XP
    Tsushimi, K
    Tsushimi, M
    Kawauchi, S
    Oga, A
    Furuya, T
    Sasaki, K
    CANCER LETTERS, 2001, 170 (02) : 183 - 189
  • [37] Expression of p21WAF1/CIP1, soft tissue sarcomas:: A comparative immunohistochemical study with p53 and Ki-67
    Pindzola, JA
    Palazzo, JP
    Kovatich, AJ
    Tuma, B
    Nobel, M
    PATHOLOGY RESEARCH AND PRACTICE, 1998, 194 (10) : 685 - 691
  • [38] The second BRCT domain of BRCA-1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter
    Chai, YL
    Cui, JQ
    Shao, NS
    Reddy, ESP
    Rao, VN
    ONCOGENE, 1999, 18 (01) : 263 - 268
  • [39] P21WAF1/Cip1 gene expression in primary human hepatocellular carcinoma and its relationship with P53 gene mutation
    Sun Baohua
    Wu Zhongbi
    Ruan Youbing
    Yang Mulan
    Liu Bing
    Journal of Tongji Medical University, 1999, 19 (1) : 1 - 5
  • [40] The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter
    YuLi Chai
    Jian-qi Cui
    Ningsheng Shao
    E Shyam P Reddy
    Veena N Rao
    Oncogene, 1999, 18 : 263 - 268